Still No Revenues for Cannabis Science (OTC:CBIS)
Medical Cannabis Photo
By futurefilmworks from Pixabay
Stock promotion is serious business and commonplace in the SmallCap arena, but it is a necessary demon for the undercapitalized companies to market themselves and attract more investors. Stocks using this usually effective method are trying to expand their investor base and ramp up volume, but don’t fall in love with all the bells and whistles because one thing for sure… they are almost always short-lived. It’s just simple market correction that’s all… you can’t expect a stock to gain 50 percent one day and not give any back the next. The best move is to buy early (i.e. when you first receive the promo e-mail) or not at all because after a couple of hours most of the buying is done anyway and the price usually dips back down.
One company from the SmallCap space this morning that looks to be under some sort of promotion campaign is Cannabis Science (OTC:CBIS) because the last news from this company was issued way back in September. Also, a look into their financials will show you that they are a development stage company with no revenue and an accumulative deficit of nearly $ 60 million.
Already today Cannabis Science has traded nearly 2 million shares and hit a 52-week high of almost 6 cents. This stock trades so rarely that it does not even have an average daily volume so stock promotion is definitely one of the possibilities. Another important factor to point out is the business they are engaged in – medical marijuana – is still in such an early stage, both politically and economically, no one really knows what is going to happen with it. The time-frame for profitability could be 20 years instead of 5 like many hope. Definitely do your due diligence and research on this company before clicking the “buy” tab because you could be sitting on these 6 cent shares for quite a while.
Cannabis Science is one of the companies engaged in pharmaceutical grade medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. In sum, Cannabis Science are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
For more information visit
http://www.worldmarketmedia.com/779/section.aspx/2510/post/still-no-revenues-for-cannabis-science-otccbis
WorldMarketMedia.com (The Global Online Investment Community) is a high traffic stock market, news data website providing cutting edge new media products and services to publicly traded companies worldwide. Our Editor’s Desk authors insightful real-time coverage on the economy, the capital markets and their listed companies.
